FI4279070T3 - Koostumus sisältäen 5-metoksi-N,N-dimetyylitryotamini-bentsoaattisuolaa - Google Patents
Koostumus sisältäen 5-metoksi-N,N-dimetyylitryotamini-bentsoaattisuolaa Download PDFInfo
- Publication number
- FI4279070T3 FI4279070T3 FIEP23157604.2T FI23157604T FI4279070T3 FI 4279070 T3 FI4279070 T3 FI 4279070T3 FI 23157604 T FI23157604 T FI 23157604T FI 4279070 T3 FI4279070 T3 FI 4279070T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- dose
- inhaler
- benzoate
- dry powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008961.1A GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GBGB2008968.6A GB202008968D0 (en) | 2020-06-12 | 2020-06-12 | Phamaceutical composition |
| GBGB2008964.5A GB202008964D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GB2019241.5A GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| GBGB2101634.0A GB202101634D0 (en) | 2021-02-05 | 2021-02-05 | Pharmaceutical composition |
| GBGB2101640.7A GB202101640D0 (en) | 2021-02-05 | 2021-02-05 | Pharmaceutical composition |
| GBGB2102095.3A GB202102095D0 (en) | 2021-02-15 | 2021-02-15 | Pharmaceutical composition |
| GBGB2102100.1A GB202102100D0 (en) | 2021-02-15 | 2021-02-15 | Pharmaceutical composition |
| GBGB2105047.1A GB202105047D0 (en) | 2021-04-08 | 2021-04-08 | Pharmaceutical composition |
| GBGB2105049.7A GB202105049D0 (en) | 2021-04-08 | 2021-04-08 | Pharmaceutical composition |
| GBGB2105462.2A GB202105462D0 (en) | 2021-04-16 | 2021-04-16 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4279070T3 true FI4279070T3 (fi) | 2025-01-02 |
Family
ID=76641719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP23157604.2T FI4279070T3 (fi) | 2020-06-12 | 2021-06-14 | Koostumus sisältäen 5-metoksi-N,N-dimetyylitryotamini-bentsoaattisuolaa |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US11518742B2 (https=) |
| EP (5) | EP4279070B1 (https=) |
| JP (2) | JP7795482B2 (https=) |
| KR (1) | KR20230024378A (https=) |
| CN (2) | CN119613319A (https=) |
| AU (1) | AU2021289147A1 (https=) |
| BR (1) | BR112022025306A2 (https=) |
| CA (1) | CA3187020A1 (https=) |
| DK (1) | DK4279070T3 (https=) |
| ES (1) | ES3007386T3 (https=) |
| FI (1) | FI4279070T3 (https=) |
| IL (1) | IL298871A (https=) |
| NZ (1) | NZ795865A (https=) |
| WO (2) | WO2021250435A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| WO2021250435A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| JP2024520017A (ja) * | 2021-05-26 | 2024-05-21 | マインドセット ファーマ インコーポレイテッド | 幻覚剤と脂肪酸との併用 |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| KR20240132439A (ko) | 2021-07-22 | 2024-09-03 | 지에이치 리서치 아일랜드 리미티드 | 트립타민 유도체의 제조 방법 |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4408412A4 (en) * | 2021-09-30 | 2025-07-16 | ATAI Life Sciences AG | COMPOSITIONS AND METHODS FOR TREATING HEADACHES |
| EP4159192A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| AU2022413759A1 (en) * | 2021-12-13 | 2024-06-27 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023137094A1 (en) * | 2022-01-12 | 2023-07-20 | Eleusis Therapeutics Us, Inc. | Psilocin benzoate formulation for intravenous infusion |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| PT4313945T (pt) | 2022-03-27 | 2024-06-11 | Gh Res Ireland Limited | Sal de hidrobrometo cristalino de 5-meo-dmt |
| KR20250005175A (ko) * | 2022-03-27 | 2025-01-09 | 지에이치 리서치 아일랜드 리미티드 | 양극성 장애의 치료를 위한 5-meo-dtm |
| US20250213532A1 (en) | 2022-03-27 | 2025-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| CA3267555A1 (en) * | 2022-10-26 | 2024-05-02 | Atai Therapeutics, Inc. | Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use |
| WO2024105379A1 (en) * | 2022-11-14 | 2024-05-23 | Beckley Psytech Limited | Formulations of 5-meo-dmt |
| GB202306256D0 (en) | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| EP4727525A1 (en) * | 2023-06-13 | 2026-04-22 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025024637A1 (en) * | 2023-07-25 | 2025-01-30 | Atai Therapeutics, Inc. | Compositions for limiting sympathomimetic effects of psychedelic therapeutics |
| WO2025068714A1 (en) * | 2023-09-28 | 2025-04-03 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| WO2025153822A1 (en) | 2024-01-18 | 2025-07-24 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) powder formulations |
| WO2026068950A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders |
| WO2026068951A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | 5-methoxy-dmt for use in the treatment of depression |
| WO2026068953A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Methods and kits comprising 5-meo-dmt for use in treating depression |
| WO2026078143A1 (en) * | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2774763A (en) | 1956-12-18 | Preparation of amides of lysergic age | ||
| US2997470A (en) | 1956-03-05 | 1961-08-22 | Lilly Co Eli | Lysergic acid amides |
| US3078214A (en) | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| US3224945A (en) | 1963-05-06 | 1965-12-21 | College Of Pharmacy | Process for the production of ergot alkaloids |
| BE792515A (fr) | 1971-12-10 | 1973-06-08 | Sandoz Sa | Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments |
| CH578565A5 (en) | 1972-12-07 | 1976-08-13 | Sandoz Ag | N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity |
| HU172649B (hu) | 1975-04-24 | 1978-11-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh biologicheski aktivnykh lizergamidov |
| GB1584464A (en) | 1977-04-19 | 1981-02-11 | Farmaceutici Italia | Ergot alkaloids |
| EP0026899A1 (de) | 1979-10-09 | 1981-04-15 | Sandoz Ag | Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung |
| WO2001015677A2 (en) * | 1999-08-31 | 2001-03-08 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
| US20020173549A1 (en) | 2000-11-08 | 2002-11-21 | Wurtman Richard J. | Compositions and methods for treatment of mild cognitive impairment |
| KR100523257B1 (ko) * | 2000-12-29 | 2005-10-24 | 삼성전자주식회사 | 포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물 |
| BR0312176A (pt) | 2002-06-21 | 2005-04-05 | Suven Life Sciences Ltd | Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario |
| ES2383768T3 (es) * | 2006-06-28 | 2012-06-26 | Chelsea Therapeutics Inc. | Composiciones farmacéuticas que comprenden droxidopa |
| AU2007309390A1 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating Alzheimer's disease |
| ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
| WO2010054202A2 (en) | 2008-11-06 | 2010-05-14 | Leon Rosenberg | Package of pills useful for titration and method of titrating a patient |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| AU2011313814B2 (en) * | 2010-10-07 | 2015-12-24 | Eaglepharma Pty Ltd | Combination therapy for the treatment of depression and other non-infectious diseases |
| EP2771341A4 (en) * | 2011-10-28 | 2015-09-23 | Univ Texas | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| CN103816150A (zh) | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
| US20180147142A1 (en) | 2015-05-19 | 2018-05-31 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| CN120555529A (zh) | 2018-03-08 | 2025-08-29 | 指南针探路者有限公司 | 生产色胺的方法 |
| US10813116B2 (en) | 2018-05-11 | 2020-10-20 | Apple Inc. | Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems |
| CA3148256A1 (en) | 2018-06-21 | 2019-12-26 | Robert John Petcavich | Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| JP2022512230A (ja) | 2018-12-14 | 2022-02-02 | ペア セラピューティクス インコーポレイテッド | ブプレノルフィン含有製品の誘導を最適化するためのデジタル治療構成要素 |
| MD3927338T2 (ro) | 2019-02-22 | 2025-03-31 | Gh Res Ireland Limited | Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale |
| EP4353314A3 (en) * | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| AU2020228289B2 (en) | 2019-02-27 | 2026-02-05 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| WO2021003467A1 (en) * | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| GB201911024D0 (en) * | 2019-08-01 | 2019-09-18 | Beckley Found | Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders |
| AU2020337903A1 (en) | 2019-08-25 | 2022-03-31 | Caamtech, Inc. | Alkyl quarternary ammonium tryptamines and their therapeutic uses |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| AU2021254855A1 (en) | 2020-04-16 | 2022-09-15 | Pike Therapeutics, Inc. | Transdermal micro-dosing delivery of psychedelics derivatives |
| US20210322743A1 (en) | 2020-04-20 | 2021-10-21 | Indian Institute Of Technology Bombay | Microneedle array patch for drug delivery and production method thereof |
| IL297669A (en) | 2020-05-01 | 2022-12-01 | Emergex Usa Corp | Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions |
| IL297912A (en) | 2020-05-05 | 2023-01-01 | Univ Basel | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
| WO2021250435A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN113288883A (zh) | 2021-05-24 | 2021-08-24 | 河南科技大学 | 一种长效缓解抑郁微针贴片及其制备方法 |
-
2021
- 2021-06-14 WO PCT/GB2021/051476 patent/WO2021250435A1/en not_active Ceased
- 2021-06-14 CA CA3187020A patent/CA3187020A1/en active Pending
- 2021-06-14 EP EP23157604.2A patent/EP4279070B1/en active Active
- 2021-06-14 EP EP21735379.6A patent/EP3941583B9/en active Active
- 2021-06-14 IL IL298871A patent/IL298871A/en unknown
- 2021-06-14 JP JP2022576811A patent/JP7795482B2/ja active Active
- 2021-06-14 DK DK23157604.2T patent/DK4279070T3/da active
- 2021-06-14 CN CN202411802400.4A patent/CN119613319A/zh active Pending
- 2021-06-14 BR BR112022025306A patent/BR112022025306A2/pt unknown
- 2021-06-14 EP EP24208163.6A patent/EP4595962A3/en active Pending
- 2021-06-14 EP EP24213283.5A patent/EP4483957A3/en active Pending
- 2021-06-14 FI FIEP23157604.2T patent/FI4279070T3/fi active
- 2021-06-14 NZ NZ795865A patent/NZ795865A/en unknown
- 2021-06-14 EP EP21735380.4A patent/EP3941904A1/en not_active Withdrawn
- 2021-06-14 ES ES23157604T patent/ES3007386T3/es active Active
- 2021-06-14 CN CN202180055398.7A patent/CN116056762B/zh active Active
- 2021-06-14 AU AU2021289147A patent/AU2021289147A1/en active Pending
- 2021-06-14 KR KR1020237001336A patent/KR20230024378A/ko active Pending
- 2021-06-14 WO PCT/GB2021/051475 patent/WO2021250434A1/en not_active Ceased
-
2022
- 2022-04-27 US US17/660,873 patent/US11518742B2/en active Active
- 2022-04-27 US US17/660,981 patent/US11518743B2/en active Active
- 2022-08-04 US US17/817,548 patent/US11603353B2/en active Active
- 2022-09-26 US US17/935,256 patent/US11680044B2/en active Active
-
2023
- 2023-02-01 US US18/162,976 patent/US20230348381A1/en active Pending
- 2023-05-02 US US18/310,822 patent/US20230382858A1/en not_active Abandoned
-
2025
- 2025-12-18 JP JP2025264947A patent/JP2026048894A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4279070T3 (fi) | Koostumus sisältäen 5-metoksi-N,N-dimetyylitryotamini-bentsoaattisuolaa | |
| GB2596884A8 (en) | Pharmaceutical composition | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| AU2010335594B2 (en) | Synergistic antiviral composition and use thereof | |
| JP2018199688A5 (https=) | ||
| JP2009269923A5 (https=) | ||
| FI2265257T4 (fi) | Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi | |
| JP2014515373A5 (https=) | ||
| US20160051494A1 (en) | Multi-dose medication kit for treating anaphylaxis | |
| JP2014514271A5 (https=) | ||
| Tu et al. | Localized delivery of nanomedicine and antibodies for combating COVID-19 | |
| RU2018143564A (ru) | Карбоновая кислота, предназначенная для лечения/предупреждения заложенности носа | |
| RU2020112519A (ru) | Ингалятор и сетка для ингалятора | |
| SE0303091D0 (sv) | Combined doses of tiotropium andfluticasone | |
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| ES2441733T3 (es) | Formulación del nebulizador | |
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| JPWO2022096708A5 (https=) | ||
| JP2013522295A5 (https=) | ||
| JP2021532098A5 (https=) | ||
| WO2014205030A1 (en) | Pulmonary administration of rotigotine | |
| EP4228643A1 (en) | Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses | |
| WO2023139108A1 (en) | Treprostinil for the treatment of pulmonary hypertension | |
| JPWO2023118896A5 (https=) | ||
| CN104582690A (zh) | 用于经鼻部施用的组合物 |